PURPOSE The current clinical recommendations posit the deployment of specific approved radiolabeled prostate-specific membrane antigen-ligand positron emission tomography (PSMA PET) for detecting metastatic prostate cancer during primary staging. Nevertheless, the precise efficacy of such ligands in localizing intraprostatic tumours (index tumour) and T-staging is not well established. Consequently, the objective of this inquiry is to ascertain the diagnostic accuracy of PSMA-PET in the tumour staging of newly diagnosed prostate cancer by means of a meta-analysis that integrates studies utilizing histological confirmation as the reference standard. METHODS In this study, we conducted a systematic literature search of the PubMed, Em...
Background: Despite the acknowledged diagnostic detection rate of prostate-specific membrane antigen...
Background: Despite the acknowledged diagnostic detection rate of prostate-specific membrane antigen...
Introduction: Prostate specific membrane antigen (PSMA) positron emission tomography (PET) with comp...
PURPOSE The current clinical recommendations posit the deployment of specific approved radiolabel...
Our purpose was to determine and compare the interobserver variability of 3 clinically frequently us...
Context : In December 2020, the US Food and Drug Administration approved a 68Ga-labeled prostate-spe...
Context: In December 2020, the US Food and Drug Administration approved a 68Ga-labeled prostate-spec...
CONTEXT: Management of newly diagnosed prostate cancer (PCa) is guided in part by accurate clinical ...
Context: Management of newly diagnosed prostate cancer (PCa) is guided in part by accurate clinical ...
Positron-emission tomography (PET) with prostate-specific membrane antigen (PSMA) has been increasin...
Background: Despite the acknowledged diagnostic detection rate of prostate-specific membrane antigen...
Background: Despite the acknowledged diagnostic detection rate of prostate-specific membrane antigen...
Background: Despite the acknowledged diagnostic detection rate of prostate-specific membrane antigen...
Background: Despite the acknowledged diagnostic detection rate of prostate-specific membrane antigen...
Background: Despite the acknowledged diagnostic detection rate of prostate-specific membrane antigen...
Background: Despite the acknowledged diagnostic detection rate of prostate-specific membrane antigen...
Background: Despite the acknowledged diagnostic detection rate of prostate-specific membrane antigen...
Introduction: Prostate specific membrane antigen (PSMA) positron emission tomography (PET) with comp...
PURPOSE The current clinical recommendations posit the deployment of specific approved radiolabel...
Our purpose was to determine and compare the interobserver variability of 3 clinically frequently us...
Context : In December 2020, the US Food and Drug Administration approved a 68Ga-labeled prostate-spe...
Context: In December 2020, the US Food and Drug Administration approved a 68Ga-labeled prostate-spec...
CONTEXT: Management of newly diagnosed prostate cancer (PCa) is guided in part by accurate clinical ...
Context: Management of newly diagnosed prostate cancer (PCa) is guided in part by accurate clinical ...
Positron-emission tomography (PET) with prostate-specific membrane antigen (PSMA) has been increasin...
Background: Despite the acknowledged diagnostic detection rate of prostate-specific membrane antigen...
Background: Despite the acknowledged diagnostic detection rate of prostate-specific membrane antigen...
Background: Despite the acknowledged diagnostic detection rate of prostate-specific membrane antigen...
Background: Despite the acknowledged diagnostic detection rate of prostate-specific membrane antigen...
Background: Despite the acknowledged diagnostic detection rate of prostate-specific membrane antigen...
Background: Despite the acknowledged diagnostic detection rate of prostate-specific membrane antigen...
Background: Despite the acknowledged diagnostic detection rate of prostate-specific membrane antigen...
Introduction: Prostate specific membrane antigen (PSMA) positron emission tomography (PET) with comp...